Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma

ConclusionHyperprogression is rare in melanoma patients treated with immune checkpoint inhibitors. Our data question if hyperprogression really is a biological entity in metastatic melanoma.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research